These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29228564)

  • 1. Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in
    Bartalucci N; Calabresi L; Balliu M; Martinelli S; Rossi MC; Villeval JL; Annunziato F; Guglielmelli P; Vannucchi AM
    Oncotarget; 2017 Nov; 8(57):96710-96724. PubMed ID: 29228564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
    Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
    PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
    Bartalucci N; Guglielmelli P; Vannucchi AM
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?
    Chen E; Mullally A
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):268-76. PubMed ID: 25696866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin inhibits JAK2V617F activity in MPN cells by activating AMPK and PP2A complexes containing the B56α subunit.
    Kawashima I; Kirito K
    Exp Hematol; 2016 Dec; 44(12):1156-1165.e4. PubMed ID: 27576133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins.
    Huang H; Liu J; Yang L; Yan Y; Chen M; Li B; Xu Z; Qin T; Qu S; Wang L; Huang G; Chen Y; Xiao Z
    Blood Sci; 2023 Oct; 5(4):258-268. PubMed ID: 37941916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2.
    Ishida S; Akiyama H; Umezawa Y; Okada K; Nogami A; Oshikawa G; Nagao T; Miura O
    Oncotarget; 2018 Jun; 9(42):26834-26851. PubMed ID: 29928488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms.
    Gorantla SP; Prince G; Osius J; Dinesh DC; Boddu V; Duyster J; von Bubnoff N
    Front Oncol; 2024; 14():1430833. PubMed ID: 39091915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
    Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
    Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
    Mueller A; Bachmann E; Linnig M; Khillimberger K; Schimanski CC; Galle PR; Moehler M
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1601-15. PubMed ID: 22543857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
    Schnöder TM; Eberhardt J; Koehler M; Bierhoff HB; Weinert S; Pandey AD; Nimmagadda SC; Wolleschak D; Jöhrens K; Fischer T; Heidel FH
    J Cancer Res Clin Oncol; 2017 May; 143(5):807-820. PubMed ID: 28233092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
    Kirstein MM; Boukouris AE; Pothiraju D; Buitrago-Molina LE; Marhenke S; Schütt J; Orlik J; Kühnel F; Hegermann J; Manns MP; Vogel A
    Liver Int; 2013 May; 33(5):780-93. PubMed ID: 23489999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in
    Zhang Q; Shi C; Han L; Jain N; Roberts KG; Ma H; Cai T; Cavazos A; Tabe Y; Jacamo RO; Mu H; Zhao Y; Wang J; Wu SC; Cao F; Zeng Z; Zhou J; Mi Y; Jabbour EJ; Levine R; Tasian SK; Mullighan CG; Weinstock DM; Fruman DA; Konopleva M
    Oncotarget; 2018 Jan; 9(8):8027-8041. PubMed ID: 29487712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
    Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
    Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [JAK2V617F mutation and p-STAT5 protein expression in peripheral blood cells of patients with myeloproliferative neoplasm and their relations with clinical features].
    Chen YX; Li Y; Zhang LY; Liu X; Shan NN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1398-404. PubMed ID: 23257441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer.
    Britschgi A; Andraos R; Brinkhaus H; Klebba I; Romanet V; Müller U; Murakami M; Radimerski T; Bentires-Alj M
    Cancer Cell; 2012 Dec; 22(6):796-811. PubMed ID: 23238015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia.
    Daenthanasanmak A; Lin Y; Zhang M; Bryant BR; Petrus MN; Bamford RN; Thomas CJ; Miljkovic MD; Conlon KC; Waldmann TA
    Transl Oncol; 2021 Jan; 14(1):100913. PubMed ID: 33129109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRL-induced ERalpha gene expression is mediated by Janus kinase 2 (Jak2) while signal transducer and activator of transcription 5b (Stat5b) phosphorylation involves Jak2 and a second tyrosine kinase.
    Frasor J; Barkai U; Zhong L; Fazleabas AT; Gibori G
    Mol Endocrinol; 2001 Nov; 15(11):1941-52. PubMed ID: 11682625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.